CN100343257C - 治疗固有活性脱髓鞘炎性病症的ccr1拮抗剂 - Google Patents

治疗固有活性脱髓鞘炎性病症的ccr1拮抗剂 Download PDF

Info

Publication number
CN100343257C
CN100343257C CNB2003801086866A CN200380108686A CN100343257C CN 100343257 C CN100343257 C CN 100343257C CN B2003801086866 A CNB2003801086866 A CN B2003801086866A CN 200380108686 A CN200380108686 A CN 200380108686A CN 100343257 C CN100343257 C CN 100343257C
Authority
CN
China
Prior art keywords
compound
application
disease
treatment
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003801086866A
Other languages
English (en)
Chinese (zh)
Other versions
CN1738824A (zh
Inventor
肯尼斯·G.·卡尔森
杰拉尔丁·C.·B.·哈里曼
肖米·格霍什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CN1738824A publication Critical patent/CN1738824A/zh
Application granted granted Critical
Publication of CN100343257C publication Critical patent/CN100343257C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB2003801086866A 2002-11-13 2003-11-12 治疗固有活性脱髓鞘炎性病症的ccr1拮抗剂 Expired - Fee Related CN100343257C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42594702P 2002-11-13 2002-11-13
US60/425,947 2002-11-13
PCT/US2003/035817 WO2004043965A1 (en) 2002-11-13 2003-11-12 Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease

Publications (2)

Publication Number Publication Date
CN1738824A CN1738824A (zh) 2006-02-22
CN100343257C true CN100343257C (zh) 2007-10-17

Family

ID=32313083

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801086866A Expired - Fee Related CN100343257C (zh) 2002-11-13 2003-11-12 治疗固有活性脱髓鞘炎性病症的ccr1拮抗剂

Country Status (24)

Country Link
US (7) US20040106639A1 (https=)
EP (2) EP1562954B1 (https=)
JP (1) JP4644491B2 (https=)
KR (1) KR101109348B1 (https=)
CN (1) CN100343257C (https=)
AR (1) AR041942A1 (https=)
AT (2) ATE325124T1 (https=)
AU (2) AU2003291452A1 (https=)
BR (1) BR0316261A (https=)
CA (1) CA2505874C (https=)
CY (1) CY1107985T1 (https=)
DE (2) DE60305063T2 (https=)
DK (1) DK1562954T3 (https=)
EA (1) EA007748B1 (https=)
ES (2) ES2346337T3 (https=)
IL (2) IL168384A (https=)
MX (1) MXPA05005105A (https=)
NO (1) NO331855B1 (https=)
PL (1) PL211022B1 (https=)
PT (1) PT1562954E (https=)
SI (1) SI1562954T1 (https=)
TW (1) TWI291467B (https=)
WO (1) WO2004043965A1 (https=)
ZA (2) ZA200504144B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US7541365B2 (en) * 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
ATE553761T1 (de) 2004-12-17 2012-05-15 Millennium Pharm Inc Solide formen eines chemokin-rezeptorantagonisten und anwendungsverfahren dafür
MX2007007599A (es) 2004-12-21 2007-12-07 Serono Lab Dervivados ciclicos de sulfonilamino y uso de los mismos.
PL1844032T3 (pl) 2005-01-31 2011-09-30 Merck Serono Sa Pochodne N-hydroksyamidu i ich zastosowanie
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
JP2009507003A (ja) 2005-09-01 2009-02-19 アレス トレーディング ソシエテ アノニム 視神経炎の治療
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
BRPI0714811A2 (pt) * 2006-07-14 2014-02-18 Lilly Co Eli Modulador de receptor de corticóide, seus sais, composições farmacêuticas compreendendo os mesmos e uso dos referidos compostos e sais na fabricação de medicamento
EP2173713B1 (en) 2007-07-24 2016-02-17 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
WO2009082526A2 (en) * 2007-10-05 2009-07-02 Pharmacopeia, Inc. Ortho pyrrolidine, benzyl-substituted heterocycle ccr1 antagonists for autoimmune diseases & inflammation
JP2011505364A (ja) * 2007-11-30 2011-02-24 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ＴＭＥＤＡを用いた５−シクロプロピル−５，１１−ジヒドロ［１］ベンゾオキセピノ［３，４−ｂ］−ピリジン−５−オールの製造方法
US20090286823A1 (en) * 2007-12-17 2009-11-19 Millennium Pharmaceuticals Inc. CCR1 Inhibitors useful for the treatment of multiple myeloma and other disorders
ATE522537T1 (de) 2008-01-11 2011-09-15 Lilly Co Eli (e)-n-ä3-ä1-(8-fluor-11h-10-oxa-1-aza-dibenzo-ä , dü-cyclohepten-5-yliden)-propylü-phenylü- methylsulfon-amid als glucocorticoid- rezeptormodulator zur behandlung rheumatoider arthritis
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009138A2 (en) * 1999-07-28 2001-02-08 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CN1289336A (zh) * 1998-01-21 2001-03-28 千禧药品公司 趋化因子受体拮抗剂和其使用方法

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80449C (https=)
DD80449A (https=)
US377729A (en) * 1888-02-07 Half to phillips
GB1003292A (en) 1960-12-08 1965-09-02 Sandoz Ag Improvements in or relating to 4-azathiaxanthene derivatives
FR1332145A (https=) 1961-06-08 1963-12-16
CH416624A (de) 1962-10-23 1966-07-15 Sandoz Ag Verfahren zur Herstellung von neuen heterocyclischen Verbindungen
NL132137C (https=) 1963-04-24
FR88751E (https=) 1963-07-09 1967-06-07
GB1085405A (en) 1963-10-14 1967-10-04 Pfizer & Co C Dibenzoxepins and dibenzthiepins
BE664609A (https=) 1964-06-01
CH421138A (de) 1965-11-04 1966-09-30 Wander Ag Dr A Verfahren zur Herstellung von Thioxanthenderivaten
US3409621A (en) * 1966-04-01 1968-11-05 Schering Corp Piperazino-aza-dibenzo-[a, d]-cycloheptenes
US3625974A (en) 1967-04-28 1971-12-07 Fujisawa Pharmaceutical Co Dibenzothiazepine derivatives
GB1206216A (en) 1967-07-18 1970-09-23 Pfizer & Co C Aminopropylidene dibenzoxepine tranquilizers
NL6905642A (https=) 1968-04-12 1969-10-14
JPS4830064B1 (https=) 1968-12-23 1973-09-17
GB1330966A (en) 1970-12-22 1973-09-19 Yoshitomi Pharmaceutical N-substituted piperidine compounds methods for their production and pharmaceutical compositions containing them
US3770729A (en) * 1970-12-22 1973-11-06 Yoshitomi Pharmaceutical N substituted piperidine compounds
GB1347935A (en) 1971-04-10 1974-02-27 Yoshitomi Pharmaceutical Piperazine derivatives methods for their production and phar maceutical compositions containing them
CA1010870A (en) * 1972-12-08 1977-05-24 Niels Lassen Thiaxanthene derivative and method
US4250176A (en) * 1976-12-21 1981-02-10 Janssen Pharmaceutica N.V. Piperazine derivatives
US4335122A (en) * 1981-03-18 1982-06-15 Hoechst-Roussel Pharmaceuticals Inc. Dihydro-dibenzoxepines-thiepines and -morphanthridones, compositions and use
DE3326641A1 (de) 1982-07-27 1984-02-02 Basf Ag, 6700 Ludwigshafen 5,6-dihydro-11-h-morphantridin-6-one, ihre herstellung und diese enthaltende arzneimittel
CA1237428A (en) * 1983-06-24 1988-05-31 Hiroshi Tanaka ¬1| benzepino¬3,4-b|pyridine derivative
ES8502099A1 (es) 1983-08-02 1984-12-16 Espanola Farma Therapeut Procedimiento de obtencion de nuevos compuestos derivados de la difenil-metilen-etilamina.
DE3402060A1 (de) * 1984-01-21 1985-08-01 Dr. Karl Thomae Gmbh, 7950 Biberach Substituierte 5,11-dihydro-6h-dibenz(b,e)azepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CS236550B1 (cs) 1984-02-02 1985-05-15 Miroslav Protiva Způsob přípravy esterů piperazinoalkanolů dibenzo(b,e)thiepinové řady a jejich solí s kyselinou maleinovou
CS236549B1 (cs) 1984-02-02 1985-05-15 Miroslav Protiva Piperazinoalkanoly dibenzo(b,e)thiepinové řady a jejich soli s kyselinou maleinovou
CS240698B1 (cs) 1984-10-12 1986-02-13 Miroslav Protiva Substituované ll-(piperidinoalkyl)-6,ll-dihydrodibenzo (b,e)thiepin-ll-karbonitrily
JPH0665664B2 (ja) 1985-01-18 1994-08-24 大塚製薬株式会社 モルフアントリジン誘導体
SE8500273D0 (sv) * 1985-01-22 1985-01-22 Leo Ab Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder
JPS6310784A (ja) 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
WO1988000049A1 (fr) 1986-06-26 1988-01-14 Kyowa Hakko Kogyo Co., Ltd. Agent antiarythmique
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
IT8721978A0 (it) 1987-09-21 1987-09-21 Angeli Inst Spa Nuovi derivati ammidinici triciclici.
US4882351A (en) * 1987-10-14 1989-11-21 Roussel Uclaf Tricyclic compounds
AU612437B2 (en) * 1987-12-14 1991-07-11 Kyowa Hakko Kogyo Co. Ltd. Tricyclic compounds
EP0411048A1 (en) 1988-04-28 1991-02-06 Schering Corporation Novel benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
CA1338625C (en) * 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
DE3827093A1 (de) 1988-08-10 1990-02-15 Nattermann A & Cie Verfahren zur herstellung von hochreinem ebselen
DE3838912A1 (de) * 1988-11-17 1990-05-23 Thomae Gmbh Dr K Mittel zur behandlung von akuten und chronischen obstruktiven atemwegserkrankungen
JPH0694464B2 (ja) * 1991-01-23 1994-11-24 協和醗酵工業株式会社 三環式化合物およびその中間体
EP0511477B1 (en) * 1991-03-11 1996-07-10 Kyowa Hakko Kogyo Co., Ltd. Indole derivatives
WO1992016226A1 (en) 1991-03-19 1992-10-01 Smithkline Beecham Corporation Il-1 inhibitors
WO1992020681A1 (en) 1991-05-23 1992-11-26 Schering Corporation Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
WO1993002081A1 (en) 1991-07-23 1993-02-04 Schering Corporation Novel benzopyrido piperylidene compounds, compositions, methods of manufacture and methods of use
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US5679703A (en) * 1992-09-16 1997-10-21 Kyowa Hakko Kogyo, Co., Ltd. Tricyclic compounds having ACAT inhibiting activity
DE69333885T2 (de) 1992-11-10 2006-09-14 Genentech, Inc., South San Francisco C-c ckr-1, ein c-c chemokin rezeptor
US5538986A (en) * 1993-12-06 1996-07-23 Schering Corporation Tricyclic derivatives, compositions and methods of use
MY113463A (en) * 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
AU5270796A (en) 1995-04-07 1996-10-23 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters th ereof
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
WO1996031470A1 (en) 1995-04-07 1996-10-10 Novo Nordisk A/S Novel heterocyclic compounds
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
UA54385C2 (uk) 1995-04-07 2003-03-17 Ново Нордіск А/С N-заміщені азагетероциклічні карбонові кислоти та їх ефіри, спосіб їх одержання, фармацевтична композиція та спосіб лікування
JPH0940662A (ja) 1995-05-24 1997-02-10 Kyowa Hakko Kogyo Co Ltd 三環式化合物
US6150355A (en) * 1995-09-13 2000-11-21 Kyowa Hakko Kogyo Co., Ltd. Phenylpiperidine derivative
AU1208397A (en) 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
DE29602088U1 (de) 1996-02-07 1996-04-04 Bümach Engineering International B.V., Emmen Verschraubbarer druckmittelbetätigter Arbeitszylinder mit Verschlußteilen zur Kopplung des Zylinderrohres
DE69709647T2 (de) 1996-05-20 2002-11-07 Dupont Pharmaceuticals Research Laboratories, Inc. Cyclischer diarylalkyl diaminederivate als antogoniste von chemokinerezeptoren
JP2000516210A (ja) 1996-07-12 2000-12-05 ロイコサイト，インコーポレーテッド ケモカインレセプターアンタゴニストとその使用方法
US6323206B1 (en) 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2261633A1 (en) 1996-07-29 1998-02-05 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
IL128949A0 (en) 1996-09-13 2000-02-17 Schering Corp Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
AU4801197A (en) 1996-09-13 1998-04-02 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibit ors
CN1104427C (zh) 1996-09-13 2003-04-02 先灵公司 法呢基蛋白转移酶的三环抑制剂
CZ84199A3 (cs) 1996-09-13 1999-11-17 Schering Corporation Nové, tricyklické piperidinylové sloučeniny použitelné jako inhibitory farnesylprotein transferasy
CN1237176A (zh) 1996-09-13 1999-12-01 先灵公司 用作fpt抑制剂的三环化合物
CA2264666A1 (en) 1996-09-13 1998-03-19 Schering Corporation Substituted benzocycloheptapyridine useful as inhibitors of farnesyl-protein transferase
NZ334437A (en) 1996-09-13 2000-09-29 Schering Corp Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
CA2267500A1 (en) 1996-10-04 1998-04-16 Novo Nordisk A/S N-substituted azaheterocyclic compounds
ZA978792B (en) 1996-10-04 1998-04-06 Novo Nordisk As N-substituted azaheterocyclic compounds.
WO1998015548A1 (en) 1996-10-04 1998-04-16 Novo Nordisk A/S 1,4-disubstituted piperazines
AU5604998A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025605A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
AU5812498A (en) 1996-12-20 1998-07-17 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
AU6517398A (en) 1997-03-27 1998-10-22 Kyowa Hakko Kogyo Co. Ltd. Therapeutic agent for autoimmune diseases
ES2273413T3 (es) 1997-04-15 2007-05-01 Kyowa Hakko Kogyo Co., Ltd. Compuestos triciclicos.
US5877177A (en) * 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6040318A (en) 1997-06-25 2000-03-21 Novo Nordisk A/S Tricycle substituted with azaheterocyclic carboxylic acids
JP2002515914A (ja) 1997-06-25 2002-05-28 ノボ ノルディスク アクティーゼルスカブ 新規へテロ環式化合物
US6048856A (en) * 1997-12-17 2000-04-11 Novo Nordisk A/S Heterocyclic compounds
US6433165B1 (en) * 1998-01-21 2002-08-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6613905B1 (en) * 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2343536A1 (en) 1998-09-04 2000-03-16 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
MXPA04004826A (es) 1998-09-04 2004-08-11 Millenium Pharmaceuticals Inc Antagonista del receptor de quimioquinas y metodos para su uso.
US6503926B2 (en) * 1998-09-04 2003-01-07 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US20020169155A1 (en) * 1998-09-04 2002-11-14 Millennium Pharmaceuticals, Inc. Chemokine receptor anagonists and methods of use therefor
AU1549500A (en) 1998-12-02 2000-06-19 Novo Nordisk A/S Use of n-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis
EP1204664A1 (en) * 1999-07-28 2002-05-15 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP1204640A2 (en) 1999-07-28 2002-05-15 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
NZ596484A (en) * 2001-11-21 2013-05-31 Millennium Pharm Inc Chemokine receptor antagonists and methods of use thereof
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
DE112005000053T5 (de) 2005-04-20 2007-05-31 Mitsubishi Denki K.K. Überstromrelais
JP4715952B2 (ja) 2009-02-18 2011-07-06 村田機械株式会社 フロッグレッグ型移載装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1289336A (zh) * 1998-01-21 2001-03-28 千禧药品公司 趋化因子受体拮抗剂和其使用方法
WO2001009138A2 (en) * 1999-07-28 2001-02-08 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor

Also Published As

Publication number Publication date
NO331855B1 (no) 2012-04-23
KR20050074609A (ko) 2005-07-18
IL210046A (en) 2015-07-30
CY1107985T1 (el) 2013-09-04
IL168384A (en) 2011-01-31
JP2006508966A (ja) 2006-03-16
DK1562954T3 (da) 2006-08-28
KR101109348B1 (ko) 2012-01-31
AU2008202965B2 (en) 2012-03-22
US7977350B2 (en) 2011-07-12
DE60305063T2 (de) 2006-11-16
EA200500803A1 (ru) 2005-10-27
TWI291467B (en) 2007-12-21
CN1738824A (zh) 2006-02-22
EP1562954B1 (en) 2006-05-03
ATE325124T1 (de) 2006-06-15
ATE468340T1 (de) 2010-06-15
MXPA05005105A (es) 2005-07-01
ES2346337T3 (es) 2010-10-14
SI1562954T1 (sl) 2006-10-31
NO20052272L (no) 2005-06-06
US20040106639A1 (en) 2004-06-03
IL210046A0 (en) 2011-07-31
CA2505874A1 (en) 2004-05-27
US20110230516A1 (en) 2011-09-22
EP1669356B1 (en) 2010-05-19
US20130289063A1 (en) 2013-10-31
TW200413347A (en) 2004-08-01
US20080139602A1 (en) 2008-06-12
WO2004043965A1 (en) 2004-05-27
AR041942A1 (es) 2005-06-01
US7732459B2 (en) 2010-06-08
BR0316261A (pt) 2005-10-11
ES2261979T3 (es) 2006-11-16
EP1669356A1 (en) 2006-06-14
PL377715A1 (pl) 2006-02-06
ZA200607868B (en) 2008-01-08
PT1562954E (pt) 2006-07-31
EA007748B1 (ru) 2006-12-29
US20100249174A1 (en) 2010-09-30
EP1562954A1 (en) 2005-08-17
US9334283B2 (en) 2016-05-10
PL211022B1 (pl) 2012-03-30
CA2505874C (en) 2012-07-17
HK1086011A1 (en) 2006-09-08
AU2008202965A1 (en) 2008-07-31
HK1074046A1 (en) 2005-10-28
JP4644491B2 (ja) 2011-03-02
DE60332663D1 (de) 2010-07-01
US20050288319A1 (en) 2005-12-29
AU2003291452A1 (en) 2004-06-03
US20150005338A1 (en) 2015-01-01
DE60305063D1 (de) 2006-06-08
ZA200504144B (en) 2007-04-25
US8394817B2 (en) 2013-03-12

Similar Documents

Publication Publication Date Title
CN100343257C (zh) 治疗固有活性脱髓鞘炎性病症的ccr1拮抗剂
CN1067428A (zh) 奎宁环衍生物
CN1208415A (zh) 抑制血管生成的哒嗪胺
CN1074764C (zh) 苯并噁嗪酮多巴胺d4受体拮抗剂
CN1007352B (zh) 新的4h-1-苯并吡喃-4-酮的生产方法
CN1048726C (zh) 取代的4－苯基噻唑衍生物,其制法和含它们的药物组合物
CN1032754C (zh) 免疫刺激性6-芳基-5，6-二氢咪唑并[2，1-b]噻唑衍生物的制备方法
CN1122666C (zh) 新的2,3－二氢化茚醇化合物,其制备方法和包含它们的药物组合物
CN1009826B (zh) 制备喹啉基化合物的方法
CN1061043C (zh) 苯并异噻唑基取代的氨甲基苯并二氢吡喃
CN1128030A (zh) 具有中枢神经系统活性的杂环胺
EP2286811B1 (en) Chemokine receptor antagonists and methods of use thereof
CN1067391C (zh) 哌啶基甲基噁唑烷酮
CN1321158A (zh) 作为药物的三环△3－哌啶
CN1287555A (zh) 具有tnf和pde－iv抑制活性的杂环化合物n－氧化物
CN1304409A (zh) 用于治疗抑郁症的吲哚－3－基－环己胺衍生物(5－ht1受体拮抗剂)
CN1331692A (zh) 作为α2－拮抗剂的苯并异噁唑和苯基酮
CN1220690C (zh) 5－苯甲酰氨基－1，3－二氧环类化合物及其制备方法以及在制备蛋白激酶c抑制剂药物中的应用
CN1022325C (zh) 咪唑烷二酮衍生物的制备方法
CN1053448C (zh) 用作抗增殖药物及garft抑制剂的化合物
HK1019736B (en) New indanol compounds, a process for their preparation and pharmaceutical compositions containing them
JP5640256B2 (ja) ＰＰＡＲγアゴニスト
CN1265656A (zh) 作为抗肿瘤和抗转移试剂的邻位取代的羟基苯并呋喃－3－酮衍生物
HK1154504B (en) Chemokine receptor antagonists and methods of use thereof
HK1086011B (en) Ccr1 antagonists for the treatment of i.a demyelinating inflammatory disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071017

Termination date: 20191112